NCT07356609Not yet recruitingNot Applicable
Primary Care ERectile Function Outcome Registry for Men
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 255
Study Overview
Brief Summary
The PERFORM registry is a structured, real-world data platform designed to systematically capture patient characteristics, disease severity and treatment patterns of Erectile Dysfunction (ED) across Pakistan. By reflecting routine clinical practice, an ED registry provides valuable insights into the disease epidemiology, unmet needs, and variations in care across populations. It supports evidence-based decision-making, helps identifying early predictors, and inform guideline development, health policy, and personalized management strategies in male sexual health.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult male above 18 years of age
- •Patient reports erectile dysfunction (symptomatic).
- •Patient is eligible to be prescribed sildenafil by treating clinician.
Exclusion Criteria
- •If at any other PDE-5 inhibitor (sildenafil, tadalafil, vardenafil, avanafil)
- •Concurrent use of organic nitrates (any form: glyceryl trinitrate, isosorbide mononitrate/dinitrate) - absolute contraindication
- •Recent or unstable cardiovascular disease
- •Myocardial infarction or stroke in last 3 months
- •Unstable angina
- •Uncontrolled arrhythmia or heart failure NYHA III-IV
- •Resting hypotension (SBP < 90 mmHg) or uncontrolled hypertension (SBP > 180 mmHg) per treating clinician
- •Known severe hepatic impairment or severe renal impairment on dialysis (if local clinician deems unsafe)
- •Known hypersensitivity to sildenafil or excipients
- •Concomitant use of potent CYP3A4 inhibitors (e.g., ritonavir) - unless clinician documents safe plan/dose adjustment
Investigators
Similar Trials
Recruiting
Not Applicable
Real World Evidence Study of SYN023 in Children Exposed to RabiesNCT07327307Synermore Biologics (Suzhou) Co., Ltd.232
Not yet recruiting
Not Applicable
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By ElranatamabNCT07320326Peking University People's Hospital159
Not yet recruiting
Not Applicable
Testing the Impact of Pre-visit Priming for MedicationsNCT07281131Brigham and Women's Hospital1,700
Not yet recruiting
Not Applicable
PrEP4U: Assessing the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Follow-up Choice on PrEP PersistenceNCT07335289Massachusetts General Hospital400
Recruiting
Not Applicable
Evaluation of the Clinical Performance of the PremaSure Kit to Assess Premature Delivery Risk in Symptomatic Pregnant PatientsNCT07307365Rea Diagnostics SA800